Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,001–8,100 of 15,747
Fucaloro, S. P., Yacoubian, V., Piltch-Loeb, R. N., et al. (2022) · Vaccines · doi:10.3390/vaccines10030348 · Cited by 8
“In December 2020, biotech companies Pfizer and Moderna released vaccines under emergency use authorization, which governments across the globe prioritized for the elderly, the vulnerable, and essential workers [2,3].”
BackgroundOptimal allocation of vaccines in a pandemic
Gans, J. S. (2022) · Oxford Review of Economic Policy · doi:10.1093/oxrep/grac027 · Cited by 8
ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study
Fontana, R. J., Li, Y., Vuppalanchi, R., Kleiner, D. E., Gu, J., Shroff, H., Wagner, L. B. V., Watkins, P. B., & on behalf of the US DILIN study group (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002702 · Cited by 9
Harenberg, J., Marchetti, M., & Falanga, A. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1658-4852 · Cited by 8
Understanding COVID-19 Vaccines Today: Are T-cells Key Players?
Shafqat, A., Arabi, T. Z., Sabbah, B. N., Abdulkader, H. S., Shafqat, S., Razak, A., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Vaccines · doi:10.3390/vaccines10060904 · Cited by 8
“Pfizer-BioNTech (BNT162b2) SARS-CoV-2 (Wuhan-Hu-1) 95% [36] 96.”
Specker, C., Aries, P. M., Braun, J., Burmester, G. R., Fischer‐Betz, R., Hasseli, R., Holle, J. U., Hoyer, B. F., Iking‐Konert, C., Krause, A., et al. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01056-6 · Cited by 12
Decoding pH‐Driven Phase Transition of Lipid Nanoparticles
Trollmann, M. F. W., & Böckmann, R. A. (2026) · Small · doi:10.1002/smll.202511381 · Cited by 16
Lau, D. K., Aresu, M., Planche, T., Tran, A., Lazaro-Alcausi, R., Duncan, J., Kidd, S., Cromarty, S., Begum, R., Rana, I., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac230 · Cited by 7
Socioeconomic Inequities in Vaccine Hesitancy Among Native Hawaiians and Pacific Islanders
Samoa, R. A., Ðoàn, L. N., Saw, A., et al. (2022) · Health Equity · doi:10.1089/heq.2022.0033 · Cited by 8
Majumder, M. A. A., Singh, K., Johnson, W., Rajasundaram, A., Gupta, S., Gaur, U., Kumar, S., Chatterjee, M., Rabbi, A. M. F., Sangishetti, V. P., et al. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s390364 · Cited by 11
Community Masks - from an Emergency Solution to an Innovation Booster for the Textile Industry
Batt, T., Herwig, G., Annaheim, S., Clement, P., Furer, L. A., Hirsch, C., Varanges, V., Çağlar, B., Michaud, V. J., Wang, J., et al. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.249 · Cited by 9
Diamantopoulos, P. T., Stafylidis, C., Vlachopoulou, D., Kontandreopoulou, C., Giannakopoulou, N., Vardaka, M., Mpouhla, A., Mastrogianni, E., Variami, E., Galanopoulos, A. G., et al. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221090150 · Cited by 8
Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction
Saha, A., Choudhary, S., Walia, P., Kumar, P., & Tomar, S. (2025) · Virology · doi:10.1016/j.virol.2025.110394 · Cited by 9
Schreiber, K. I., Graversgaard, C., Petersen, R., Jakobsen, H., Bojesen, A. B., Krogh, N. S., Glintborg, B., Hetland, M. L., & Hendricks, O. (2021) · Vaccines · doi:10.3390/vaccines10010035 · Cited by 8
“The effectiveness of the vaccines can therefore not be applied to a patient population on DMARDs (conventional, biologic or targeted synthetic) as these patients were not included in the above-mentioned studies [6,7].”
BackgroundJoshi, R., Sharma, S., Kapoor, D. U., Prajapati, B. G., Huanbutta, K., & Sriamornsak, P. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00774 · Cited by 11
Malaria vaccine approaches leveraging technologies optimized in the COVID-19 era
Kanoi, B. N., Maina, M., Likhovole, C., Kobia, F., & Gitaka, J. (2022) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2022.988665 · Cited by 13
“BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA encoding the SARS-CoV-2 full-length spike protein modified by two proline mutations (41).”
BackgroundChen, D., Wen, Y.-H., Lin, W.-T., & Hsu, F.-P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.941497 · Cited by 12
“The frequency of headaches was 39% to 80% after mRNA vaccination (9, 10) and from 39% to 66% after adenoviral vector vaccination (11).”
BackgroundFusco, M. D., Moran, M. M., Cane, A. D., et al. (2021) · medRxiv · doi:10.1101/2021.10.12.21264707 · Cited by 8
Ho, M., Zanwar, S., Buadi, F. K., Ailawadhi, S., Larsen, J. T., Bergsagel, P. L., Binder, M., Chanan-Khan, A. A., Dingli, D., Dispenzieri, A. A., et al. (2022) · Blood · doi:10.1182/blood.2022017616 · Cited by 7
Tylicki, P., Polewska, K., Och, A., Susmarska, A., Puchalska-Reglińska, E., Parczewska, A., Biedunkiewicz, B., Szabat, K., Renke, M., Tylicki, L., et al. (2022) · Viruses · doi:10.3390/v14030451 · Cited by 10
“Vaccines significantly reduced the risk of severe disease and mortality during the course of COVID-19 [10].”
BackgroundYilmaz, I. C., İpekoğlu, E. M., Saraydar, B., Bildik, T., Aksoy, A. G. B., Evcili, İ., Turay, N., Sürücü, N., Bulbul, A., Guvencli, N., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126787 · Cited by 12
Ferawati, K., Liew, K., Aramaki, E., & Wakamiya, S. (2022) · JMIR Infodemiology · doi:10.2196/39504 · Cited by 7
Virological Traits of the SARS-CoV-2 BA.2.87.1 Lineage
Zhang, L., Dopfer-Jablonka, A., Nehlmeier, I., Kempf, A., Graichen, L., Hampel, N. C., Cossmann, A., Stankov, M., Ramos, G. M., Schulz, S. R., et al. (2024) · bioRxiv · doi:10.3390/vaccines12050487 · Cited by 8
Robinson, A. G., Mazurek, A., Xu, M., & Gong, Y. (2021) · Current Oncology · doi:10.3390/curroncol29010006 · Cited by 8
“In addition, both the U.S. Food and Drug Administration and Health Canada have authorized the use of Pfizer-BioNTech and Moderna vaccines as booster doses in those 18 years of age and older at least 6 months after completion of the primary series.”
BackgroundRNA-based therapeutic opportunities for the treatment of kidney diseases
Prins, J., Biscans, A., van Zonneveld, A. J., Frazier, K. S., & van der Veer, E. P. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01011-7 · Cited by 13
“202,203).”
Kaya, O. (2021) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.905059 · Cited by 18
Impact of the COVID-19 pandemic on uveitis patient care
Vu, A. F., Kodati, S., Lin, P., Bodaghi, B., & Emami-Naeini, P. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-320368 · Cited by 8
What Every Diabetologist Should Know about SARS-CoV-2: State of Knowledge at the Beginning of 2021
Abramczyk, U., & Kuzan, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051022 · Cited by 8
Saá, P., Fink, R. V., Dawar, H., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad253 · Cited by 8
“It is known that naive individuals are much more susceptible to severe disease than vaccinated individuals [13, 14].”
BackgroundPietrasanta, C., Ronchi, A., Crippa, B. L., Artieri, G., Ballerini, C., Crimi, R., Mosca, F., & Pugni, L. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.883953 · Cited by 9
“Pregnant women were initially excluded from clinical trials on COVID-19 vaccines, for theoretical safety and ethical concerns (6, 7).”
BackgroundUpdated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Perrotta, C., Fenizia, C., Carnovale, C., Pozzi, M., Trabattoni, D., Cervia, D., & Clementi, E. (2023) · Vaccines · doi:10.3390/vaccines11091481 · Cited by 12
“Other systemic side effects reported were fatigue, fever, headache, myalgias, and arthralgias, with most occurring within 1 to 2 days following vaccination and lasting between 24 and 48 h [78,97].”
BackgroundInfluentialHosseininezhad, M., Khatami, S. S., Saadat, S., Ahmadabad, M. A., Choshal, H. G., Marvasti, A. H., & Soleimani, Z. G. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05562-y · Cited by 12
da Silva, J. A., & da Silva, L. D. A. (2021) · Uniedusul Editora eBooks · doi:10.51324/86010749.11 · Cited by 7
Yamashita, K., Suzuki, A. K., Takebayashi, S., Toguchi, A., Ogitani, K., Niizeki, N., Nagura, O., Furuhashi, K., Iwaizumi, M., & Maekawa, M. (2022) · Vaccines · doi:10.3390/vaccines10071050 · Cited by 7
“In particular, the efficacies of two mRNA vaccines, BNT162b2 (Pfizer-BioNTech, Mainz, Germany) and mRNA-1273/TAK-919 (Moderna, USA), have been reported to be 95% [1,2].”
BackgroundResponse to: COVID‐19 re‐infection. Vaccinated individuals as a potential source of transmission
Schiavone, M., Gasperetti, A., Mitacchione, G., Viecca, M., & Forleo, G. B. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13544 · Cited by 9
(2021) · doi:10.1101/2021.04.15.21255550 · Cited by 8
“The current coronavirus disease 2019 (COVID-19) pandemic leads to a high morbidity and mortality especially among patients with kidney failure ( 1 ).”
BackgroundResultInfluentialBonura, F., Genovese, D., Amodio, E., Calamusa, G., Sanfilippo, G. L., Cacioppo, F., Giammanco, A., Grazia, S. D., & Ferraro, D. (2022) · Vaccines · doi:10.3390/vaccines10060874 · Cited by 8
“Immunity to SARS-CoV-2, induced by vaccination or by natural infection, has been shown to reduce the risk of clinically significant outcomes [17,26].”
BackgroundLi, F., Xu, W., Zhang, X., Wang, W., Su, S., Han, P., Wang, H., Xu, Y., Li, M., Fan, L., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04955-3 · Cited by 8
A material toolbox for engineering targeted lipid nanoparticles for RNA therapies
Yoo, S., Ang, M. J. Y., Murray, A. M., & Mitchell, M. J. (2026) · Materials Today · doi:10.1016/j.mattod.2025.12.034 · Cited by 10
Waldman, S., Adams, J. Y., Albertson, T. E., Juarez, M. M., Myers, S. L., Atreja, A., Batra, S., Foster, E. E., Huynh, C. V., Liu, A. Y., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.336 · Cited by 9
Luo, S., Yin, L., Liu, X., & Wang, X. (2025) · Biosensors · doi:10.3390/bios15030198 · Cited by 9
“The first WHO-authorized [161,162].”
Nosocomial COVID‐19 infection in the era of vaccination and antiviral therapy
McNeil, T., Zhang, F., Moffatt, S., Emeto, T. I., & Tucker, E. C. (2023) · Internal Medicine Journal · doi:10.1111/imj.16298 · Cited by 9
Alkhalifah, J. M., Seraihi, A. A., Al‐Tawfiq, J. A., Alshehri, B. F., Alhaluli, A. H., Alsulais, N. M., Alessa, M. M., Seddiq, W., Aljeri, T., Qahtani, M. H., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1043696 · Cited by 10
“Indeed, The Saudi Food and Drug Authority (SFDA) granted emergency use authorization for the use of Pfizer-BioNTech COVID-19 vaccine on the same day the Phase III trial results were published (6, 7).”
BackgroundMethodInfluentialLiver injury on admission linked to worse outcomes in COVID-19: an analysis of 14,138 patients
Chela, H. K., Tallon, E. M., Baskett, W. I., Gangu, K., Tahan, V., Shyu, C., & Daglilar, E. S. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-21-94 · Cited by 8
COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman
Ning, W., Xu, W., Cong, X. S., Fan, H., Gilkeson, G. S., Wu, X., Heather, H., & Jiang, W. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102896 · Cited by 9
Wan, E. Y. F., Ng, V. W. S., Chang, R. S., Yan, V. K. C., Chui, C. S. L., Wong, C. K. H., Li, X., Lai, F. T. T., Chan, E. W., Hung, I. F., et al. (2022) · Epilepsia · doi:10.1111/epi.17436 · Cited by 10
Cutaneous manifestations following COVID‐19 vaccination: a multicentric descriptive cohort
Massip, E., Marcant, P., Font, G., Faiz, S., Duvert‐Lehembre, S., Alcaraz, I., Vermersch‐Langlin, A., Véron, M., Macaire, C., Faure, K., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17883 · Cited by 8
Kunc, M., Whitehead, B. J., Østergaard, L. J., Tolstrup, M., Benn, C. S., Wejse, C. M., & Nejsum, P. L. (2025) · Journal of Clinical Immunology · doi:10.1007/s10875-025-01977-w · Cited by 9
“Nevertheless, both vaccines confer some protection through activation of both innate and adaptive immune responses [11, 12].”
Vakhrusheva, A., Kudriavtsev, A. V., Kryuchkov, N. A., Deev, R. V., Frolova, M. E., Blagodatskikh, K. А., Djonovic, M., Nedorubov, A. A., Odintsova, E. S., Ivanov, A. V., et al. (2022) · Vaccines · doi:10.3390/vaccines10081290 · Cited by 9
“The mRNA-based vaccines such as mRNA-1273/Spikevax (Moderna) or BNT162b2/ Comirnaty (Pfizer/Biontech) are reported to be highly effective [27,28].”
BackgroundHonda, T., Toyama, S., Matsumoto, Y., Sanada, T., Yasui, F., Koseki, A., Kono, R., Yamamoto, N., Kamishita, T., Kodake, N., et al. (2024) · Vaccines · doi:10.3390/vaccines12070794 · Cited by 8
“…the potent virus-reducing effect of S–CVP is potentially attributable to its ability to induce cell-mediated immunity, in addition to humoral immunity. mRNA-based vaccines used worldwide are highly efficient against COVID-19 by strongly inducing neutralizing antibodies and cellular immunity [4,30].”
BackgroundPouriayevali, M. H., Teimoori, A., Esmaeili, S., Abdoli, A., Doroud, D., Salehi-Vaziri, ., Shahali, M., Kadkhodazadeh, M., Sabouni, T., Khosravi, M. A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.066 · Cited by 7
“These features make them promising candidates for developing COVID-19 vaccines.”
BackgroundInfluentialNonhuman primate models of pediatric viral diseases
Kandiyil, V. V. K., & Paris, K. D. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1493885 · Cited by 9
Could Vaccination against COVID-19 Trigger Immune-Mediated Inflammatory Diseases?
Liakou, A. Ι., Tsantes, A. G., Routsi, E., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164617 · Cited by 8
“Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly throughout the world in 2019–2020, resulting in the coronavirus disease (COVID-19) pandemic [1].”
BackgroundMcConaghy, M., Sartaj, M., Conway, B. R., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.169 · Cited by 8
Cisneros, M. C. C., Anderson, E. J., Hampton, B. K., Parotti, B., Sarkar, S., Taft-Benz, S., Bell, T. A., Blanchard, M. W., Dillard, J. A., Dinnon, K. H., et al. (2024) · Vaccines · doi:10.3390/vaccines12010103 · Cited by 9
“These vaccine platforms, which include mRNA, vectored, recombinant protein, virus like particles (VLPs), and inactivated whole virus (iCoV) vaccines, have been proven to safely elicit protective immunity against SARS-CoV-2 [3–6].”
BackgroundSakai, A., Morishita, T., & Matsunami, H. (2022) · Transplant International · doi:10.3389/ti.2022.10321 · Cited by 10
“Pioneering studies on vaccines against SARS-CoV-2 have verified their safety and efficacy in general populations (1).”
BackgroundStructural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins
Prandi, I. G., Mavian, C. N., Giombini, E., Gruber, C. E. M., Pietrucci, D., Borocci, S., Abid, N., Beccari, A. R., Talarico, C., & Chillemi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158680 · Cited by 7
Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients
Pascale, S. P., Nuccorini, R., Pierri, T., Mare, R. D., Fabio, L., Lerose, E., Merlino, M. A., Schiavo, P., Amendola, A., Brucoli, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892331 · Cited by 8
“This has been performed with fundamentally two different vaccine technologies used in parallel: one based on SARS-CoV-2 mRNA (7, 8) and the other based on adenoviral vector (9, 10), both of which are capable of”
BackgroundMethodMarkovinović, A., Quan, J., Herauf, M., et al. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002337 · Cited by 8
“Gastrointestinal symptomsmay follow SARS-CoV2 vaccination, which could be confused for IBD disease activity (1,2).”
BackgroundImmune Response after mRNA COVID-19 Vaccination in Lung Transplant Recipients: A 6-Month Follow-Up
Tobudic, S., Benazzo, A., Koblischke, M., Schneider, L., Blüml, S., Winkler, F., Schmidt, H. M., Vorlen, S., Haslacher, H., Perkmann, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10071130 · Cited by 10
“In healthy individuals, COVID-19 mRNA vaccines are highly immunogenic [5,6].”
BackgroundHumoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Miyazaki, R., Miyagi, K., Yoshida, M., et al. (2023) · Renal Replacement Therapy · doi:10.1186/s41100-022-00452-1 · Cited by 8
“The best way to address this problem is to vaccinate against COVID-19 [3].”
BackgroundInfluentialStandardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma
Gilchuk, P., Thomsen, I. P., Yoder, S. M., Brady, E. J., Chappell, J. D., Stevens, L. J., Denison, M. R., Sutton, R. E., Chen, R. E., VanBlargan, L. A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103602 · Cited by 7
Counting on COVID-19 vaccine: Insights into the current strategies, progress and future challengesPreprint
Kandimalla, R. J. L., Chakraborthy, P., Vallamkondu, J., et al. (2021) · doi:10.31219/osf.io/uy7mp · Cited by 8
LinearDesign: Efficient Algorithms for Optimized mRNA Sequence DesignPreprint
Zhang, H., Zhang, L., Li, Z., Liu, K., Liu, B., Mathews, D. H., & Huang, L. (2020) · arXiv (Cornell University) · Cited by 14
Production and Distribution of mRNA Vaccines: SARS-CoV-2 Experience
Tanoğlu, E. G. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.17 · Cited by 8
A case of psoriatic spondyloarthritis exacerbation triggered by COVID‐19 messenger RNA vaccine
Ohmura, S., Hanai, S., Ishihara, R., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18013 · Cited by 8
Central concepts for randomized controlled trials and other emerging trial designs
Heindel, P. V., Dieffenbach, B. V., Freeman, N. L. B., McGinigle, K. L., & Menard, M. T. (2022) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2022.10.004 · Cited by 10
Real world SARS-COV-2 vaccine effectiveness in a Miami academic institution
Mallow, C. M., Ferreira, T., Shukla, B. S., Warde, P. R., Sosa, M. A., Parekh, D. J., & Gershengorn, H. B. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.01.066 · Cited by 7
“1 and 95% efficacious at preventing symptomatic SARS-COV-2 infection [1,2].”
BackgroundEvaluating COVID-19 vaccines in the real world
Mills, E. J., & Reis, G. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00194-5 · Cited by 10
Aminolysis of Highly Branched Poly(β-amino ester)s for Efficient mRNA Delivery
Yong, H., Li, Z., Lin, L., Liu, S., Feng, C., Geng, S., Fu, T., Chen, Z., & Zhou, D. (2025) · Chemistry of Materials · doi:10.1021/acs.chemmater.4c03450 · Cited by 8
Hederman, A. P., Natarajan, H., Wiener, J. A., Wright, P. F., Bloch, E. M., Tobian, A. A. R., Redd, A. D., Blankson, J. N., Rottenstreich, A., Zarbiv, G., et al. (2022) · medRxiv · doi:10.1101/2022.09.15.22280000 · Cited by 8
Lauritsen, M. P., Leineweber, T. D., Hansen, C. B., Schneider, U. V., Talbot, A. L., Skytte, A., Petersen, J. H., Johannsen, T. H., Zedeler, A., Albrethsen, J., et al. (2023) · Andrology · doi:10.1111/andr.13494 · Cited by 11
Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination
Ohmura, S., Ohkubo, Y., Ishihara, R., Otsuki, Y., & Miyamoto, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0293-22 · Cited by 8
Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines
Sánchez-Álvarez, E., Quiroga, B., & de Sequera, P. (2021) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2021.09.001 · Cited by 8
Abebe, E. C., Ayele, T. M., Muche, Z. T., Mariam, A. B. T., Baye, N. D., Agidew, M. M., & Dejenie, T. A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2104059 · Cited by 10
“effects of the COVID 19 vaccines in several countries around the globe.(5,11,24,27,28) But no population-level data on adverse effects after COVID-19 vaccination was available in Ethiopia, and it was unclear which vaccines were associated with which”
BackgroundAdvances in Research on COVID-19 Vaccination for People Living with HIV
Jin, J., Wang, X., Carapito, R., Moog, C., & Su, B. (2022) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000065 · Cited by 8
“To date, limited studies have included PLWH in approved phase II/III vaccine trials([24]); in Moderna and Pfizer's mRNA-1273 and BNT162b2 mRNA vaccine trials, the proportion of PLWHwas <1%.([25,26]) Although the original SARS-CoV-2 mRNA vaccine trials found near-universal robust immune responses in the general populat…”
BackgroundMemedovich, A., Steele, B. J., Orr, T., Hollis, A., Salmon, C., Hu, J., Zinszer, K., Williamson, T. S., & Beall, R. F. (2025) · BMJ Public Health · doi:10.1136/bmjph-2024-000926 · Cited by 11
Meta-Analysis of the Dynamics of the Emergence of Mutations and Variants of SARS-CoV-2
Castonguay, N., Zhang, W.-D., & Langlois, M.-A. (2021) · medRxiv · doi:10.1101/2021.03.06.21252994 · Cited by 2
Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand
Intawong, K., Chariyalertsak, S., Chalom, K., Wonghirundecha, T., Kowatcharakul, W., Thongprachum, A., Chotirosniramit, N., Noppakun, K., Khwanngern, K., Teacharak, W., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284130 · Cited by 9
‘COVID vaccine arm’ may present after both mRNA vaccines vaccination
Gregoriou, S., Kleidona, I. A., Tsimpidakis, A., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17614 · Cited by 8
Vascularite leucocytoclasique et néphrite interstitielle aiguë après vaccin à SARS-CoV-2 inactivé
Missoum, S., Lahmar, M., & KHELLAF, G. (2021) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2021.10.006 · Cited by 8
“[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Zhu, G., Yang, Y., & Sun, T. (2022) · Biomaterials Science · doi:10.1039/d2bm00011c · Cited by 8
Rajmohan, P., Jose, M., Thomas, J., Krishna, S., Antony, B., Gopinathan, U. U., Iyyapan, E. M., Porinchu, R. M., Jose, P., Raphael, L., et al. (2022) · Current Drug Safety · doi:10.2174/1574886317666220207120649 · Cited by 6
Patel, J. S., Zhan, S., Siddiqui, Z. A., Dzomba, B. J., & Wu, H. (2023) · Methods of Information in Medicine · doi:10.1055/s-0042-1760248 · Cited by 9
Covid-19 Vaccination in Pregnancy: A Systematic Review
Pratama, N. R., Wafa, I. A., Budi, D. S., et al. (2021) · medRxiv · doi:10.1101/2021.07.04.21259985 · Cited by 6
A single immunization with cellular vaccine confers dual protection against SARS‐CoV ‐2 and cancer
Shimizu, K., Ueda, S., Kawamura, M., Satoh, M., & Fujii, S. (2022) · Cancer Science · doi:10.1111/cas.15434 · Cited by 7
COVID-19—from emerging global threat to ongoing pandemic crisis
Brust, K. B., Papineni, V., Columbus, C., & Arroliga, A. C. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2068940 · Cited by 9
“1% efficacy, respectively, against the ancestral SARS-CoV2 strain.(44,45) Both deliver the coronavirus spike protein to the immune system via an RNA vehicle.”
BackgroundSteffes, V. M., MacDonald, S., Crowe, J., Murali, M. M., Ewert, K. K., Li, Y., & Safinya, C. R. (2023) · The European Physical Journal E · doi:10.1140/epje/s10189-023-00388-2 · Cited by 7
Marchese, A. M., Zhou, X., Kinol, J., Underwood, E., Woo, W., McGarry, A., Beyhaghi, H., Áñez, G., Toback, S. L., & Dunkle, L. M. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.054 · Cited by 7
“Despite this, vaccine efficacy estimates against hospitalization were absent from the publications associated with the pivotal trials of most widely utilized COVID-19 vaccines [7,8].”
BackgroundConcerns and challenges in clinics-guided nanovaccines design and applications
Gao, Y., Hua, S., Dong, X., Zhang, K., Zhang, X., & Yang, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.041 · Cited by 8
“BNT162b2 and mRNA-1273 have demonstrated safety and efficacy against SARS-CoV-2, achieving protection rates of 95% and 94.1%, respectively, in clinical trials (NCT04368728, NCT04470427) 154,155 .”
InfluentialWang, Y., Wang, S., Huang, L., Mao, W., Li, F., Lin, A., Zhao, W., Zeng, X., Zhang, Y., Yang, D., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.041 · Cited by 8
Klamer, T. A., Linschoten, M., & Asselbergs, F. W. (2022) · Netherlands Heart Journal · doi:10.1007/s12471-022-01677-9 · Cited by 11
Gagelmann, N., Passamonti, F., Wolschke, C., Massoud, R., Niederwieser, C., Klyuchnikov, E., Adjallé, R., Mora, B., Ayuk, F., & Kröger, N. M. (2021) · Haematologica · doi:10.3324/haematol.2021.280163 · Cited by 91
Hamel, L., Poirier‐Gravel, F., Paré, M., Tardif, R., Comeau, M., Lavoie, P., Langlois, A., Goulet, M., Michaud, D., & D’Aoust, M. (2025) · Plant Biotechnology Journal · doi:10.1111/pbi.70075 · Cited by 8
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.